Early Australian experience in the maintenance of schizophrenia management with 3-monthly paliperidone palmitate.

CONCLUSIONS: Convenient 3-monthly dosing was preferred by clinicians and patients, and symptoms were adequately managed. This has the potential to improve adherence and lead to better outcomes as patients only need four intramuscular doses per year. PMID: 30047801 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30047801?dopt=Abstract

Source: Australasian Psychiatry - July 26, 2018 Category: Psychiatry Authors: Pai N, Warden M Tags: Australas Psychiatry Source Type: research

More News: Australia Health | Invega | Invega Sustenna | Psychiatry | Schizophrenia